がん免疫療法を促進するための制御物理バリアの開発(Giving T Cells a Break: Controlled Physical Barrier Created to Boost Cancer Immunotherapy)

ad

2025-07-14 中国科学院(CAS)

中国科学院国家ナノ科学センターの梁興傑教授らが、がん免疫療法を強化する新技術「バイオミメティック物理バリア(BPB)」を開発。BPBは体内でゲル化する温感応性ハイドロゲルで、腫瘍内に注入後、一時的にT細胞と腫瘍細胞の接触を遮断し、T細胞の疲弊を遅延。近赤外線でバリアを解除すると、蓄積されたT細胞が高い殺傷能を発揮し、腫瘍抑制効果が向上。また、バリア形成中に疲弊前駆T細胞(Tpex)が増加し、より持続的な免疫応答が誘導された。本手法は「免疫リズム制御」と呼ばれ、他の免疫療法との併用も期待されている。
<関連情報>

がん免疫療法のためのバイオミメティック物理的バリアによるT細胞-腫瘍細胞相互作用の制御 Controlling T cell–tumor cell interaction with a biomimetic physical barrier for cancer immunotherapy

Yuxuan Zhang, Jinjin Wang, Guangchao Qing, +13 , and Xing-Jie Liang
Proceedings of the National Academy of Sciences  Published:July 8, 2025
DOI:https://doi.org/10.1073/pnas.2500589122

Significance

Cancer immunotherapy often fails because infiltrating T cells in the tumor microenvironment are suppressed by immunosuppressive signals, leading to dysfunction and exhaustion. This study demonstrates a therapeutic strategy based on a physical barrier created by a hydrogel, which establishes a protective zone for T cells within the tumor microenvironment. This approach enables T cell accumulation and delays T cell exhaustion process, effectively suppressing tumor growth. When combined with OX40 antibody therapy, this strategy achieves a 50% tumor cure rate. These findings provide a perspective for cancer treatment, bridging materials science and immunology to address critical challenges in immunotherapy.

Abstract

Cancer immunotherapy has shown tremendous promise in various cancers. However, current strategies, such as immune checkpoint blockade, primarily restore exhausted T cells but provide only transient efficacy, as the rapid clearance of antibodies. Their limited durability is further hindered by persistent T cell-tumor cell interactions that accelerate T cell exhaustion. To prevent T cells from sustained exposure to these interactions, we present a hydrogel-based biomimetic physical barrier (BPB) here to create a “protective zone” for T cells. The BPB temporarily blocks T cell-tumor cell interactions and shields T cells from inactivation and exhaustion, allowing them to accumulate and maintain their functional activity in the tumor microenvironment. After sufficient T cell accumulation, the dismantling of BPB triggered by near-infrared light irradiation-induced gel-sol transition will restore the interaction between T cells and tumor cells. This controlled re-exposure allows the accumulated T cells to attack the tumor cells in a more activated and anti-exhaustion state, maximizing their tumor-killing potential. Moreover, BPB not only enhances immediate tumor regression but also triggers systemic immune activation and durable memory responses, enabling long-term protection against tumor rechallenge and effective control of multifocal tumors. Collectively, our BPB for modulating the T cell-tumor cell interaction has great prospects for advancing cancer immunotherapy.

医療・健康
ad
ad
Follow
ad
タイトルとURLをコピーしました